Following U.S. election volatility some analysts have updated their recommended target prices on shares of Sunesis Pharmaceuticals, Inc. (SNSS). According to the most recently released broker notes, 1 analyst has a …
Sunesis Pharmaceuticals
The stock is now traded at around $2.45. The impact to the portfolio due to this purchase was 0.95%. The holdings were 940,000 shares as of 2016-12-31. New Purchase: Sunesis Pharmaceuticals Inc (SNSS) Boxer …
Boxer Capital
The Emergent stock underperformed the Zacks classified Medical-Biomed ... Celgene Corporation CELG and Sunesis Pharmaceuticals, Inc. SNSS. While Cellectis sports a Zacks Rank #1 (Strong Buy), Sunesis Pharma …
Revenue
If you check you will find that SNSS stock has a topline or revenue of $3.06M for 2015 as per this Sunesis Pharma revenue chart. Investors look for stocks with a growing top line. Bottom line: The Bottomline or the net …
Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. They generate significant returns for investors to justify their large fees and they …
Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced the pricing of underwritten offerings of (i) …
SNSS, Sunesis Pharmaceuticals (NASDAQ: SNSS) has said that voreloxin improved the survival rate for …
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here. Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced that it has filed a Certificate of Amendment to its …
The stock’s market cap is $81.01 million. The stock has a 50 day moving average price of $3.84 and a 200-day moving average price of $3.96. Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings …
Sunesis Pharmaceuticals